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ABSTRACT
According to current estimations  95% of multi-
exonic human protein-coding genes undergo
alternative splicing (AS). However, for 4000 human
proteins in PDB, only 14 human proteins have
structures of at least two alternative isoforms.
Surveying these structural isoforms revealed that
the maximum insertion accommodated by an
isoform of a fully ordered protein domain was
5 amino acids, other instances of domain changes
involved intrinsic structural disorder. After collect-
ing 505 minor isoforms of human proteins with
evidence for their existence we analyzed their
length, protein disorder and exposed hydrophobic
surface. We found that strict rules govern the
selection of alternative splice variants aimed to
preserve the integrity of globular domains: alterna-
tive splice sites (i) tend to avoid globular domains or
(ii) affect them only marginally or (iii) tend to
coincide with a location where the exposed hydro-
phobic surface is minimal or (iv) the protein is
disordered. We also observed an inverse correlation
between the domain fraction lost and the full length
of the minor isoform containing the domain,
possibly indicating a buffering effect for the
isoform protein counteracting the domain trunca-
tion effect. These observations provide the basis
for a prediction method (currently under develop-
ment) to predict the viability of splice variants.
INTRODUCTION
The decade following the publication of the complete
human genome has seen dramatic developments in
sequencing technologies, which in turn generated a
plethora of new sequence data, both genomic and
expressed (i.e. cDNAs and ESTs). Alternative splicing
(AS) is one of the ﬁelds that gained the most from these
revolutionary advances. While in the pre-genomic era
most complexities in human biology setting apart Homo
sapiens from lower organisms were attributed to a high
number of human genes, estimated to be at least 100000
(1), 10 years later much of this proteomic diversity is
thought to come from the high number of sequence
variants generated by AS, coming from only  24000
protein-coding genes (2). Recent studies found that
AS events could be detected in  92–97% of multi-exonic
human genes (3,4). Advancement of new technologies
such as tissue-speciﬁc quantitative microarray (5) and
next-generation sequencing (4) makes it possible to
measure the relative abundance of AS events (3,6).
To this day, most information about AS is generated on
the nucleic acid (DNA or RNA) level. While splice
junctions observed in a processed RNA have been
fruitful in delineating different aspects of tissue-speciﬁc
AS variants (7) it has also become clear that many splice
variants are not translated into functional proteins. One of
the mechanisms to control this is non-sense-mediated
decay (NMD), which effectively prevents the expression
of splice variants with a premature stop codon.
NMD has been shown to have a widespread coupling
with AS (8). Another surveillance system, the unfolded
protein response (UPR) (9) and the related
ERAD (endoplasmic reticulum-associated degradation)
(10) operates on splice variants that result in misfolded
proteins in the ER (11,12).
According to recent estimations (2), there are  24000
protein-coding genes in the human genome, with an
average of four isoforms per gene (13), the number of
splice variants ranging from 0 to 5–6 per gene (14) for
most gene families. However, there is still a lot of uncer-
tainty about the real number of splice variants that appear
as functional proteins for each gene, due to the limited
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level. Only recently, due to technological developments in
proteomics has this problem been tackled in a systematic
way in a genome-wide fashion (15,16). Tanner et al. (15)
combined mass spectrometry with searches in the human
genome to validate 39000 exons on the translation level
and this lead to the conﬁrmation of 40 AS events. Tress
(16) and Power (17) used a similar technique to discover
multiple alternative gene products for over a hundred
Drosophila genes and three human genes in platelet,
respectively.
AS has been observed to be coupled with intrinsic
protein disorder as such proteins are naturally less prone
to mis-folding and thus to degradation (18). In a recent
study, we have shown in connection with this phenom-
enon that chimeric proteins generated by chromosomal
translocation also tend to survive with much higher
frequency if they are disordered, for the same reason
(19). It has also become apparent (by one of us,
H. Hegyi) that natural proteins contain only intact
globular domains (20). We found that with the exception
of  10% of the protein families in Pfam (in total contain-
ing more than 10000 protein families as of today),
globular Pfam domains (21) can be reliably used to elim-
inate ‘mispredicted’ proteins (generated usually by auto-
matic pipelines, based on genomic DNA and ESTs) where
a large fraction of a globular domain is missing from the
protein in question (20,22). This approach proved very
useful in the automatic annotation process of proteins in
the Trembl (23) and Ensembl (24) databases to pinpoint
potential errors in the correct delineation of the protein
sequences in question. It has also been observed before
that AS tends to avoid globular domains (25). However,
the authors also noted that 28% of AS variants do have
split domains.
There is a large gap between structural and sequence
information available of isoforms of proteins generated
by AS. While there is a plethora of sequences of alterna-
tive splice variants for human proteins, only a handful of
protein structures of such variants (26) exist. Various
researchers predict various numbers of viable sequence
variants (27,28) but only a handful of bioinformatics
studies have dealt with the problem. However, the
discipline will apparently play a large role in determining
the functional splice variants by eliminating those that
exist as proteins only in silico.
Here we studied in detail how AS affects the integrity of
globular domains. Using human proteins in Swissprot, we
ﬁnd that there is a signiﬁcant difference with respect to
domain truncation size distribution between provisional
splice variants and those for the existence of which there
is at least some evidence. We also ﬁnd that in those cases
when there is a severe truncation of a globular domain
cutting the domain in half the exposed hydrophobic
surface is usually small, comparable to that of an intact
(sub)domain. Another survival strategy of the incomplete
domain is to have a substantial amount of intrinsic
disorder around the splice site of the AS event. These
observations together will form the foundation of a
server currently under construction we shall name
Domain Integrity Veriﬁcation of AS or DIVAS for short.
MATERIALS AND METHODS
Sequence analysis
We used the human SwissProt data set of the UniProt
knowledgebase (23,29) as a source of protein sequence,
function and AS information. We used the Swissprot
nomenclature to nominate the major and minor
isoforms (i.e. the alternatively spliced variants), and to
categorize the splice events as deletion, substitution and
insertion. In total 7101 major and 13437 minor isoforms
were extracted.
Whereas Swissprot is extensively annotated and highly
reliable for the major isoforms of the proteins, there is
relatively little information supplied for the splice
variants, especially regarding their existence as viable
proteins. For this reason, we have generated two more
data sets, with increasing level of conﬁdence with respect
to the existence of protein products.
First, we have selected those splice variants which have
a ‘name’ or ‘synonym’ in the Swissprot annotation
(as opposed to a single serial number). This group
contains 6057 splice variants of 3958 human proteins.
Whereas there is no explicit evidence for the existence of
these splice variants as proteins, their existence at the level
of mRNA has been conﬁrmed by more than one
independent study, which increases the likelihood that
they represent viable alternatives to the major isoform.
Furthermore, their number is sufﬁciently high for
statistically rigorous analyses. We call this group
‘named’ throughout this article.
Next, we created a group of minor isoforms for the
existence of which as a protein there is evidence in the
literature, usually an expression study incorporating a
western blot. By sifting through the literature provided
in the annotation part of the relevant proteins in
Swissprot, we collected 505 such human isoforms.
Because their existence is conﬁrmed at the protein
level, they represent the ultimate test case for our
concepts, although their low number in certain cases
does not allow rigorous statistical analysis. These experi-
mentally veriﬁed minor variants, enlisted in
Supplementary Table S1, are termed ‘veriﬁed’ throughout
the article.
To investigate the localisation of splice events in human
proteins, we divided the Swissprot splice events into three
groups. The most frequently occurring splice type was the
deletion of a particular protein region (n=10634), which
could result from either exon skipping or alternative
initiation. All splice events were mapped to the major
isoform. We also collected substitution (n=6635) and in-
sertion splice events (n=1467). It must be noted that the
number of insertions is skewed by the fact that Swissprot
designates the longest isoform to be the major one by
default (23). For all three splice events, we performed
random controls. We randomly selected a protein from
the data set of the major isoforms and randomly picked
a splice event from the splice-event data set of that type,
also randomly choosing the splice site in the main isoform
in question. We always matched the size of the random
data set to that of the real splice event data set.
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Domain information was obtained from the Pfam-A.full
ﬁle of the Pfam database (v23.0; 21), by extracting
Swissprot and Pfam identiﬁcation numbers and the loca-
tions of the latter. We also reconstructed all minor
isoforms using the corresponding annotations in
Swissprot. To investigate domain changes in the minor
isoforms we recorded all the instances when AS occurs
within the boundaries of a Pfam domain, truncating it,
inserting extra amino acids or substituting a part of a
domain with a different sequence. We paid special atten-
tion to the cases when a domain got truncated by an
AS event.
To determine the statistical signiﬁcance of the trunca-
tion events we generated a control group where we used
the same minor-isoform data set but randomized the
location of the AS events. As we worked with the same
sample size as in the original data set, we were able to
compare directly the occurrence of the domain truncations
in the random and original data sets. We also compared
the distribution of the relative domain truncation sizes
among the original (all human Swissprot) splice variants,
the ‘named’ ones and the randomized control group.
Disorder analysis
Disorder patterns were mapped to all major isoform
sequences by using the IUPred (30) predictor. The
disorder of a region was quantiﬁed as the percentage of
the disordered amino acids in the region, with a threshold
of 0.5 for the predicted scores of the individual residues.
3D analysis
To validate our results of sequence-based domain trunca-
tions in 3D, we also carried out a structural analysis of the
PDB entries of the affected domains to see how the
truncations caused by AS might affect the survival of
the domains in question. The approaches that have been
applied have been discussed subsequently.
Alternatively spliced variants in PDB
We collected all the human proteins that have the 3D
structure of at least two isoforms in PDB. In order to
accomplish this, we compared the sequences of both the
major and minor isoforms to ‘seqres’, containing the
sequences of all chains in PDB, using Blastp (31).
Keeping only those entries from both databases that
matched each other with a percentage identity of 90%
or higher, we selected those pairs of matches where the
major and a minor isoform of the same protein could be
mapped to different PDB entries (both with a near perfect
score). The procedure can be formalized as follows.
(i) One isoform of a human protein has a higher
sequence similarity to ‘entry 1’ of seqres than to
‘entry 2’ whereas another isoform is more similar
to ‘entry 2’ than to ‘entry 1’.
(ii) We also require that the difference between ‘entry 1’
and ‘entry 2’ is in a region where both isoforms
exist or it could happen that ‘entry 1’ and ‘entry
20 simply map to two different domains of the
protein in question.
We needed this elaborate procedure in case the isoform
and the PDB entry were not 100% identical (e.g. the latter
underwent genetic engineering to facilitate the crystalliza-
tion of the protein) but based on the overall sequence
match the PDB entry in question corresponds to that
particular isoform and is in an ‘orthologous’ relationship
with another isoform corresponding to a different PDB
entry.
This approach resulted in 15 pairs of PDB entries that
appear to have been derived from different splice variants
of the same entry in Swissprot (Table 1). One protein,
FGFR_HUMAN has three isoforms with a structure in
PDB.
The occurrence of structural domains in the splice variants
in Swissprot
We compared both the major and minor isoforms of
human proteins to ‘seqres’ and wherever feasible to
SCOP sequences (32), the latter containing the sequences
of structural domains of the PDB entries. For both of
these large-scale comparisons, we used the Blastp
program (31). We recorded sequence matches with a
percentage identity of 60% or higher and collected those
hits where >10% of the domain match was missing due to
a truncation caused by AS.
Hydrophobic surface analysis of PDB entries
For those PDB matches where a structural domain was
interrupted by an alternative splice site, we carried out a
detailed structural analysis focusing on the hydrophobic
surface potentially exposed due to domain interruption by
AS. We used the CHASA (33) method to calculate the
hydrophobic surface area as follows:
(i) We determined the nonpolar (hydrophobic) surface
area of the full PDB chain in question.
(ii) We extrapolated the ideal hydrophobic surface
values for gradually smaller intact domains of the
same type using Chothia’s formula for globular
domains (34).
(iii) We also determined the hydrophobic surface values
of the actual ‘subdomains’ of the PDB chain in
question by gradually truncating it (removing the
coordinates) in steps of 5, 10 or 20 residues, depend-
ing on the original length of the chain
(<101 residues, between 101 and 300, or >300
residues, respectively). We calculated the difference
between the two values at each truncation point we
named CHASA-diff. A typical graph of the differ-
ing values is shown for 1c47 chain A (Figure 5).
(iv) We determined the local minima for each hydropho-
bic surface difference curve generated with
CHASA-diff and compared them with domain
truncation sites in our veriﬁed data set, to see if
there is a correlation between them, i.e. if trunca-
tions preferentially happen in the vicinity of these
local minima of hydrophobic surface differences.
Rather than using only the exact PDB structures
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we compared their sequences using Blastp, and
allowed 60% or better sequence identity between a
splice variant and a PDB sequence for a splice
variant to be considered for the analysis. We
accepted as valid only those local minima that
were on average at least 200kcal deeper than the
two nearest local maxima on each side, and only
those splice sites that were in the vicinity of such
local minima, no farther than 13 residues in the
amino acid sequence. To justify the values for
these two parameters we carried out a perturbation
for both of them, explained in the ‘Results’ section.
Perl scripting
Wherever not indicated otherwise calculations were done
by self-made Perl scripts.
RESULTS
Sequence analysis of minor isoforms of human proteins in
Swissprot
Using the human Swissprot subset of the UniProt
Knowledgebase we created a data set containing 20538
isoforms (7101 major and 13437 minor), to investigate
the effects of the splice events on the protein structure
and viability. In delineating the major and minor
isoforms, we followed the nomenclature of Swissprot,
which usually nominates the longest splice variant to be
the major isoform, unless there is reason to believe
otherwise.
At ﬁrst, we determined the relative length of the
truncated domains (i.e. the remaining part divided by
the full length of the domain) and related these values to
the full length of the containing proteins. It must be noted
that all sequence analysis was carried out using the Pfam
domain annotations whereas all structural domain
analysis was done with SCOP domains. The results are
Table 1. Human alternatively spliced proteins in Swissprot with minimum two isoforms in PDB (FGFR2_HUMAN has three isoforms in PDB)
Swissprot ID Isoform numbers PDB ID1 PDB ID2 Alt splic type Difference Description
CHKA_HUMAN Isoforms 1,2 3f2r_A 2cko_A Insertion* 18 Longer isoform 3f2r has an insertion of 18 amino
acids disordered in the longer variant. In 2cko,
7 residues around the site of insertion are also
disordered
CRK_HUMAN Isoforms 1,2 2eyz_A 2eyy_A C-term+domain 96 Longer isoform 2eyz has three SH3 domains
whereas shorter 2eyy has only two. The shorter
version is oncogenic
CSF3_HUMAN Isoforms 1,2 1gnc_A 1pgr_A Insertion* 3 Longer isoform 1gnc_A has a 3 amino acid inser-
tion, missing from structure (i.e. disordered)
EDA_HUMAN Isoforms 1,3 1rj7_A 1rj8_A Insertion 2 1rj7_A has a 2-amino-acid insertion compared to
1rj8_A, structure determined. Distinct receptor
speciﬁcities
FGFR2_HUMAN Isoforms 19,14 1nun_B 3dar_A C-term+domain 120 1nun_B consists of two Ig-like domains, 3dar_A
has only one
FGFR2_HUMAN Isoforms 1,19 1djs_A 1nun_B Insertion 2 1djs_A has a 2-amino-acid insertion compared to
1nun_B, both structured
GHR_HUMAN Isoforms 1,4 1axi_B 2aew_A Insertion* 27 1axi_B is 27-amino-acid longer in N-terminus,
disordered
GNAS2_HUMAN Isoforms 1,2 1azs_C 1cul_C Insertion* 14 1azs_C has a 14-amino-acid insertion compared to
1cul_C, disordered; 1 cul_C has 5-amino-acid
disordered around the place of insertion
KHK_HUMAN Isoforms 1,2 2hqq_A 3b3l_A Alt exon 44 Same length substitution (alternative exons), both
structures are fully ordered
MK08_HUMAN Isoforms 1,3 3elj_A 1ukh_A Alt exon 12 Same length substitution (alternative exons), both
structures are fully ordered
NRX1A_HUMAN Isoforms 1,2 2r1b_A 3bod_A Insertion* 30 2r1b_A has a 30-amino-acid insertion, half of it is
ordered and forms a protruding-long helix
PTN13_HUMAN Isoforms 1,4 1q7x_A 3pdz_A Insertion 5 1q7x_A has a 5-amino-acid insertion, fully
ordered; they have a different afﬁnity to tumor
suppressor protein APC
RAC1_HUMAN Isoforms 1,2 1ryf_A 1i4t_D Insertion* 19 1ryf_A has a 19-amino-acid insertion, disordered,
also in the preceeding 15 amino acids; the
insertion induces a conformational change,
PMID:14625275
ST2B1_HUMAN Isoforms 1,2 1q1z_A 1q1q_A Alt N-term 10 1q1q_A and 1q1z_A both form helical structures
in their N-termini upon pregnenolone binding,
have different speciﬁcity
UAP1_HUMAN Isoforms 1,2 1jvd_A 1jv1_A Insertion* 17 1jvd_A has a 17-amino-acid insertion, fully
disordered. 1jv1_A is structured at the place of
insertion
The isoform numbers and the PDB identiﬁers representing the two isoforms are listed. The type of AS and the number of residues the two PDBs
differ from each other (Difference) are indicated. Asterisk next to the number shows if intrinsic disorder was also observed in one or both isoforms.
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‘veriﬁed’ group are shown, each truncated domain
indicated with a dot, whereas in Figure 1B–D data are
shown in terms of actual numbers, for the ‘veriﬁed’,
‘named’ and the total number of alternative splice
variants (in Swissprot), respectively. (For the deﬁnition
of ‘veriﬁed’, ‘named’ and ‘random’ groups of splice
variants see ‘Materials and Methods’ section.) For
the ‘veriﬁed’ group, all the truncated domains satisfy at
least one of the following two criteria: truncated domain
size/original domain size >0.6 OR truncated ‘domain
size/protein length’ <0.3, i.e. the upper left quadrant of
the rectangle is empty (Figure 1A and B). However, for
the named group and the total of Swissprot, this area is
increasingly populated (6 and 10%, respectively).
According to a  
2-test, the difference is signiﬁcant both
between the ‘veriﬁed’ and the ‘named’ group (P=0.011)
and between ‘named’ and Swissprot (P=0.0002).
After summarizing all splice events in the ‘named’/all
Swissprot/randomized Swissprot sets, it became apparent
that splice sites preferably avoid globular domains: while
11576 out of the total of 33223 ( 35%) randomized
splice sites in the Swissprot splice variants fall into a
domain, this value for the actual splice variants without
randomization is 7146 (out of 33223,  22%) and further
decreases to  9% for the ‘named’ set (1019 out of 10743
domains). However, even when the splice site falls into a
globular domain, the relative length of the remaining
domain is not evenly distributed between 0 and 1 but
strongly biased towards values close to 1, as shown in
Figure 1. ‘Retained portion’ of the truncated domains (i.e. the remaining part divided by the full length of the domain) versus their ‘relative length’
related to the full length of the containing minor isoform (i.e. the remaining part of domain divided by the full length of the protein). (A) Each
truncated domain indicated by a dot, shown for the ‘veriﬁed’ group. (B) Same data as in (A) but the population of the four quadrangles indicated
with percentage numbers. (C) Data for the named group, same representation as in (B). (D) Data for the total number of alternative splice variants in
Swissprot.
1212 Nucleic Acids Research, 2011,Vol.39, No. 4Figure 2 (also apparent from Figure 1). This bias is the
most apparent again in the ‘named’ group; i.e. there is a
strong selection against severe domain truncation in
globular domains to preserve the structural integrity of
such domains. In contrast, in the randomly generated
data set the frequencies of the various truncations were
almost uniform (except for the minor truncations caused
by the overrepresented small sized splice events). The
difference between Swissprot and the ‘named’ group was
again highly signiﬁcant (P<0.0001).
In an earlier study, Dunker and co-workers (18) found
that AS is associated with protein disorder, a plausible
association considering how much less the intrinsically
disordered regions are affected structurally by major
changes in sequence when compared to ordered regions.
However in their study, no experimental evidence for the
actual existence of the alternative protein products was
taken into consideration, and no attempt was made to
address the three different types of AS events (deletion,
substitution and insertion) separately either. As we have
considerably more data, both at the mRNA (the ‘named’
group) and protein (‘veriﬁed’ group) level, we could estab-
lish the signiﬁcance of differences between observed
splicing events and chance occurrence in most cases.
The most frequently occurring splice events are the
deletions. Comparing the frequency distribution of per-
centage disorder in the deleted protein region (Figure 3)
with the control groups using the  
2-probe, we found stat-
istically signiﬁcant differences between all groups (differ-
ence between ‘named’ and Swissprot, P=0.024; between
Swissprot and ‘random’, P<0.0001). Signiﬁcant differ-
ences could also be observed for substitutions (for the
full region replaced, signiﬁcance of difference between
‘named’ and Swissprot, P=0.01, whereas between
Swissprot and random, P<0.0001, data not shown).
Due to the relatively small sample size of insertions
(1467, compared to 6635 substitutions and 10634 dele-
tions, as described in ‘Materials and Methods’ section),
signiﬁcance could not be established between the
‘named’ group and Swissprot, however Swissprot was
signiﬁcantly more disordered than the ‘random’ group
(P<0.0001).
Alternative splice variants in PDB
We collected all the human proteins that have the 3D
structure of at least two isoforms in PDB. The results of
this exhaustive search procedure (described in
Figure 3. Frequency distribution of percentage disorder in protein
regions deleted (A) substituted (B) or disrupted by an insertion (C)
by AS in the ‘named’ group/all of Swissprot/randomized Swissprot.
The three groups were signiﬁcantly different from one another, estab-
lished by  
2-tests (P<0.05), regarding deletions (A) and substitutions
(B) but not for insertions (C), due to the small sample number of the
named group. For further details see ‘Results’ section.
Figure 2. Percentage distribution of relative domain size of domains
truncated by AS in the ‘named’/all Swissprot/randomized Swissprot
sets. Bin size increment is 0.1.
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Despite the large number of minor isoforms for human
proteins in Swissprot we found only 14 proteins for which
we could ﬁnd the structure of at least two isoforms in
PDB. For one protein, FGFR_HUMAN, there are three
different PDB structures corresponding to three different
isoforms. We indicated in the table, the type of AS that
occurred for the isoforms of each protein. The most fre-
quently occurring AS type is the insertion (here we did not
distinguish between insertions and deletions), which
occurs nine times out of the 15 cases altogether. The
length of the insert varies between 2 (EDA_HUMAN)
and 30 (NRX1A_HUMAN) amino acids.
The longest insert that has an ordered structure at the
site of the insertion in both isoforms is 5 amino acids in
the PDZ2 domain of the protein tyrosine phosphatase
PTN13_HUMAN where the two splice variants have a
different afﬁnity to the tumor suppressor protein APC
(35). The structural alignment of the two isoforms is
shown in Figure 4A.
In those proteins where the insertion is longer than
10 amino acids usually both isoforms are disordered at
the site of the insertion. This is the case for CHKA_
HUMAN, GNAS2_HUMAN, NRX1A_HUMAN and
RAC1_HUMAN. In the latter, 15 residues preceding the
insertion site are also disordered, besides the insertion
itself, which, however, induces a conformational change
in the partner protein it interacts with (36).
NRX1A_HUMAN is an interesting case study where
half of the 30-residue-long insertion is ordered and
forms a long protruding helix in the longer isoform.
In two proteins, CRK_HUMAN and FGFR2_
HUMAN one isoform had an extra domain on the
C-terminus, in both cases a full-sized domain, without
being interrupted by an alternative splice site. In one
isoform of GHR_HUMAN, there was an alternative
N-terminus; however the extra amino acids in the longer
isoform are all disordered in the relevant pdb structure,
‘1axi’.
Aside from the latter alternatives when one isoform has
an extra domain, the largest difference between the
structures of two isoforms was a 44-amino-acid-long
substitution in the hexokinase KHK_HUMAN. AS of
the KHK gene selects either one or the other of two
adjacent 135-bp exons, which represent the evolutionary
descendants of a paralogous local exon duplication (37).
The structural alignment of the two isoforms is shown in
Figure 4B. The two structures are fairly similar even
though their sequences share only 35% identity. So far
no physiological function has been found for the minor
isoform (37).
Accessible non-polar surface analysis of the human splice
variants
Hydrophobic surface analysis of PDB entries. As described
in ‘Materials and Methods’ section, we used a procedure
we called CHASA-diff to calculate the hydrophobic-
surface difference of the truncated domains at the
position of truncation compared to an intact domain of
the same type and of the size that is left of the domain
after truncation. The procedure is illustrated in Figure 5
for PDB chain 1c47A. It consists of four domains as
determined by SCOP (32), also indicated in Figure 5
(throughout this section, we used domain deﬁnitions and
boundaries as delineated by SCOP). As it is apparent from
the ﬁgure the domain boundaries coincide with hydropho-
bic surface minima, in accordance with the notion that
globular domains fold in a way that buries most of the
Figure 4. Structural isoforms of alternatively spliced human proteins.
(A) Structural alignment of the major and minor isoform in the PDZ2
domain of the protein tyrosine phosphatase PTN13_HUMAN. The
two splice variants have a different afﬁnity to the tumor suppressor
protein APC (35). Isoform 4 has a 5-residue-long insertion (colored
bright red) compared to the main isoform. This was the longest
insertion in a splice variant in PDB where both variants are ordered
at the alternative splice site. (B) The structural alignment of the two
isoforms of the hexokinase KHK_HUMAN (PDB codes: 2hqqA,
3b3lA). The minor isoform contains a 44-residue substitution, which
represents a paralogous local exon duplication (indicated with solid
blue and red colors in 2 hqqA and 3b3lA, respectively). AS of the
KHK gene selects either one or the other of two adjacent, homologous
135-bp exons.
1214 Nucleic Acids Research, 2011,Vol.39, No. 4hydrophobicity inside of the domain, building up the
hydrophobic core.
Extending the analysis to splice variants with sufﬁcient
similarity to a PDB entry. We analyzed all the truncated
domains in the ‘veriﬁed’ and ‘named’ sets, with at least
60% sequence identity to a PDB chain. After running
CHASA-diff for the PDB chain, it was checked if the
truncation site was sufﬁciently close to a local minimum
in the CHASA-diff curve and if the local minimum was
sufﬁciently deep. As explained in ‘Materials and Methods’
section, a local minimum was accepted if it was at least
200kcal deeper than the average of its two neighboring
maxima. For the vicinity of a truncation site from a local
minimum to be accepted a threshold of 13 residues was
chosen.
We perturbed the latter values by changing the energy
threshold at ﬁrst to 100, then to 300kcal whereas for the
vicinity threshold, we chose at ﬁrst 14 then 12 residues.
For each perturbed value and also for the unperturbed
ones, we calculated the ratio of the error rate (i.e. the
number of ‘bad’ versus all splice variants in that
category) for the unveriﬁed and the veriﬁed group.
Taken the unperturbed values of 200kcal and
13 residues, we found this value to be (65/364)/
(1/16)=3.03. Changing the energy threshold to 300kcal
this ratio changed to (79/364)/(2/16)=1.74; whereas for
the threshold of 100kcal this ratio resulted in (59/364)/
(1/16)=2.59. In other words, threshold=200kcal
resulted in the maximum discriminating power between
the unveriﬁed and the veriﬁed group. Perturbing the
vicinity threshold produced similar values.
We paid special attention to those splice variants where
a domain lost 10% or more of its original length due to
AS. Using Blastp, requiring at least 60% sequence identity
for matches between these splice variants in the ‘named’
set and chains in PDB we got 380 distinct matches for 331
isoforms of 187 human proteins in Swissprot matching the
sequences of 154 different chains in PDB. After evaluating
the truncated domains for their newly exposed hydropho-
bic surface, we found that 310 of the 380 matches (81.6%)
satisﬁed the above two criteria about the truncation site
being sufﬁciently close to a local minimum in the
CHASA-diff curve of the matching PDB chain.
We also looked at the truncated domain length/isoform
length ratio for these structural matches in the named set,
to see if there is any difference between the 310 energetic-
ally favorable and the 70 unfavorable matches. In accord-
ance with the results summarized in Figure 1, we found
that while the average for this ratio for the favorable set
was 0.199±0.011, for the unfavorable set it was
0.423±0.037, i.e. more than twice as big than for the
favorable ones.
The results for the ‘veriﬁed’ set are shown in Table 2.
We found that 11 out of the 12 (91.7%) isoform matches
with a truncated domain with experimental evidence for
the existence of the isoform as a functioning (or malfunc-
tioning, if its existence was implicated in cancer) protein
met the two criteria described above, the only exception
being isoform 2 of ENOA_HUMAN. The 3D structure
and the CHASA-diff values for 1pdy, the most matching
PDB chain are shown in Figure 6A, with the truncated
portion indicated. The truncation site (at 94 of the 433
residue pdb chain) is at a local maximum, presumably
cutting the smaller ﬁrst domain into half. However, it
should be also noted that the remaining portion of the
domain, i.e. residues 94–137 is only a small fraction
(0.12) of the total length of the protein, ENOA_
HUMAN-2 as also shown in Table 2. As seen in
Figure 1 and conﬁrmed for the structural matches for
the ‘named’ set, this is another indicator of the survival
of an isoform. We show the truncated structures for two
more splice variants, EDF1_HUMAN-2 and
BID_HUMAN-4, represented by PDB chains 1x57A
(Figure 6B) and 2bidA (Figure 6C), respectively. The cor-
responding CHASA-diff proﬁles are also indicated.
All the rest of the 12 truncated domains listed in Table 2
were acceptable by CHASA-diff, using the threshold
values for the depth of, and distance from, the nearest
hydrophobic energy minimum (200kcal and 13 residues,
respectively).
DISCUSSION
The number of new alternative splice variants
incorporated in various databases has been steadily
increasing in recent years [Uniprot (38), Refseq (39),
Ensembl (24), ASTD (40), AS-ALPS (41)], reaching the
point when practically all multi-exonic genes have been
found to generate alternatively spliced variants.
However, the speciﬁc instances when a minor isoform is
produced are still largely undetermined. As only
 10–20% of all AS events are conserved across two or
more species (42,43), it has been suggested that AS is also
used as a tool to regulate the expression of functional
isoforms via NMD (44) or in protein degradation
pathways (45). According to a recent paper by Melamud
and Moult (46) a considerable amount of AS is the result
of a stochastic process dependent only on the number of
introns and expression level of a gene and has no function
at all (46).
Figure 5. CHASA-diff analysis of 1c47 phosphoglucomutase-1 with
SCOP domain boundaries indicated by vertical lines. The domain
boundaries separating the four domains in the PDB structure
coincide with minima in CHASA-diff, indicating relatively small hydro-
phobic surface areas.
Nucleic Acids Research,2011, Vol.39, No. 4 1215The major cause of the uncertainty regarding the
functional isoforms is the small number of splice
variants that have been seen as expressed proteins. By
painstakingly sifting through the available annotation
for any minor variants for human proteins in Swissprot,
we identiﬁed only 505 such variants, corresponding to
<5% of all minor variants of human proteins recorded
in the 2008 release of Swissprot.
Even less is known about the 3D structure of the splice
variants. While it is becoming increasingly clear, also
supported by our results, that intrinsic protein disorder
plays a signiﬁcant role in AS (18) we also found several
globular domains that are able to survive severe trunca-
tions imposed by AS. Only a few previous works paid
attention to this important issue, i.e. structural aspects
of AS, with widely varying conclusions. While Stetefeld
and Ruegg concluded that AS may result in small
changes in protein structure (26), Birzele found evidence
in the literature that splicing events may represent
transitions between different folds in the protein
sequence-structure space (28). Wang, on the other hand,
found that splicing tends to preserve the fold and it typ-
ically takes place on the protein surface (47). Melamud
and Moult found that most splice variants would result
in proteins whose stability would be severely compromised
(13), in line with their previous paper about most AS being
the result of a stochastic process, without any biological
meaning (46).
One way to settle this issue in a conclusive way is to
look at the experimental evidence, i.e. the 3D structure of
proteins that have undergone AS. An extensive search
identiﬁed only 14 human proteins in Swissprot (Table 1)
that have the structure of at least one minor variant in
PDB and this, although not enough to make sweeping
conclusions about the structural aspects of AS tends to
support the conservative view, i.e. relatively small
changes allowed for globular folds to survive AS. Aside
from insertions/deletions/substitutions in the minor
isoforms, in two cases an entire domain gets deleted on
the C-terminus, and in one case, ST2B1_HUMAN, the
alternative isoform starts with an alternative N-terminus.
However, in none of the minor isoforms does a globular
domain get substantially truncated: the longest insertion/
deletion that is accommodated by a fold without the help
of intrinsic disorder is 5 amino acids, missing from 3pdzA.
While all of the above approaches captured some truths
about the structural aspects of AS, they are mostly obser-
vational studies, not using any rigorous measurements to
make assumptions about the existence of a splice variant
that has not been seen as a mature protein. In this article,
we analyzed several different parameters for different sets
of isoforms of human proteins, namely: (i) the length dis-
tribution of truncated domains; (ii) the ratio of the lengths
of the truncated domains and the containing isoforms; (iii)
the intrinsic protein disorder of the isoforms at the splice
site; and (iv) the newly exposed hydrophobic surface
created by the truncation and the difference between an
intact and the truncated domain (CHASA-diff).
We found that all of the above measurements differ
signiﬁcantly for a set of alternatively spliced variants
from random controls and the extent to which a difference
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1216 Nucleic Acids Research, 2011,Vol.39, No. 4can be observed usually depends on the evidence we have
for the physical existence of the isoforms as proteins. We
paid the most attention to those 505 minor isoforms for
the existence of which there is experimental evidence in the
literature. In this set, we found 12 incidences (listed in
Table 2) when a domain sufﬁciently similar (>60%
sequence identity) to a structural domain in SCOP was
truncated by AS, 11 of which were predicted to survive
the truncation using CHASA-diff with the chosen
parameters.
Regarding CHASA-diff, we also found that the local
minima often coincide with domain boundaries as expli-
citly shown for PDB chain 1c47A in Figure 5. This is a
plausible ﬁnding as the primary driving force in the
formation of globular structure is hydrophobicity (48)
and it is also the bottleneck in the survival or degradation
of a globular domain truncated by an alternative splice
site. It is further proof of the validity of our approach to
predict the survival of a truncated domain: if we see a
minimum in CHASA-diff within a domain similar in
depth to that of a boundary between two domains, we
have good reason to assume that this is a valid truncation
site, especially if the other parameters regarding the length
and disorder of the protein are favorable, too.
It must be noted that the validity of such prediction is
largely independent of the genetic mechanism that
produced the domain truncation. We used this approach
before to analyze fusion proteins generated by chromo-
somal translocations (19), a genetic process that also
can produce truncated globular domains. We found that
the truncation site of a protein kinase is remarkably close
to the boundary between the two sub-domains, also
associated with a minimum in hydrophobic surface
energy (19).
An expanded data set to include all the splice variants
from other organisms is under construction and it will
apparently help to form a more nuanced view of the
circumstances that determine the survival of AS
variants. The expanded data set together with the
observed values in hydrophobic surface area, intrinsic
protein disorder and domain truncation distribution will
be benchmarked to achieve the most discriminating power
between the negative and positive data sets. The method is
currently under development and will be made available to
the public as a server we shall name Domain Integrity
Veriﬁcation of AS or DIVAS for short.
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Figure 6. Selected truncated domains from Table 2, PDB structures and CHASA-diff hydrophobic values. The structural portions shown in gray are
removed by AS. In the CHASA-diff graphs the position of truncation is indicated by a vertical line. (A) 1x57A. The AS removes residues 67–91,
which are actually disordered, thus no hydrophobicity issues arise in this region. CHASA-diff usually predicts negative values for disordered
segments. (B) 1pdyA. This was the only match between a veriﬁed splice variant and a PDB structure (with 75% sequence identity between
isoform 2 of ENOA_HUMAN and 1pdyA) where the calculated exposed hydrophobic surface (CHASA difference between the actual and theoretical
values) at the position of truncation at residue 94 was ‘prohibitively’ high. Interestingly, Pfam predicts a coiled-coil structure for this region over a
20-residue stretch. (C) 2bidA. Our method allows a truncation at residue 87, the actual splice is at residue 99, which is within the accepted vicinity,
set at 13 residues.
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